Common stock, par value $0.0001 per share
- Symbol
- ASBP
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 2.03, 3.02, 7.01, 9.01 · 8-K
Aspire-Lakewood Holdings, Inc.
ASBPNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 10, 2026, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities…
Company context
We are an early-stage biopharmaceutical and supplements company. On February 17, 2025, we completed a merger with Aspire Biopharma, Inc. (“Old Aspire”) and changed our name from Power Up Acquisition Corp. to Aspire Biopharma Holdings, Inc. and became a Delaware corporation. The Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held company Puerto Rican corporation incorporated in September 2021.
Current securities
Recent company filings
Registered securities in this filing
Aspire Biopharma Holdings, Inc. · 8-K · Filed 2026-08-10
Warrants, each exercisable for one share of common stock
- Symbol
- ASBPW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
August 10, 2026,
the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K.
The
information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Augments revenue growth profile and diversifies Aspire’s development and commercial portfolio with new high growth business Expected to immediately improve path to profitability ESTERO, FL / August 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that the Company has completed its previously announced acquisition (the “Acquisition”) of Dura Driver Control Systems (“DCS”), a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, lightweighting, and sustainability. The acquisition is expected to enhance Aspire’s ability to deliver increased revenues…
Open exhibit ↗